Amgen Inc. (AMGN) Position Boosted by Bruderman Asset Management LLC
Bruderman Asset Management LLC raised its position in shares of Amgen Inc. (NASDAQ:AMGN) by 11.0% during the second quarter, Holdings Channel reports. The institutional investor owned 28,590 shares of the medical research company’s stock after buying an additional 2,826 shares during the period. Amgen comprises 1.4% of Bruderman Asset Management LLC’s holdings, making the stock its 24th largest position. Bruderman Asset Management LLC’s holdings in Amgen were worth $4,350,000 as of its most recent filing with the SEC.
Other large investors have also added to or reduced their stakes in the company. Integrated Wealth Management boosted its stake in Amgen by 0.3% in the second quarter. Integrated Wealth Management now owns 930 shares of the medical research company’s stock worth $141,000 after buying an additional 3 shares in the last quarter. Goelzer Investment Management Inc. boosted its stake in Amgen by 0.3% in the second quarter. Goelzer Investment Management Inc. now owns 1,604 shares of the medical research company’s stock worth $244,000 after buying an additional 5 shares in the last quarter. Nadler Financial Group Inc. boosted its stake in Amgen by 0.3% in the second quarter. Nadler Financial Group Inc. now owns 2,111 shares of the medical research company’s stock worth $321,000 after buying an additional 6 shares in the last quarter. Capital Advisors Ltd. LLC boosted its stake in Amgen by 0.6% in the second quarter. Capital Advisors Ltd. LLC now owns 1,078 shares of the medical research company’s stock worth $164,000 after buying an additional 6 shares in the last quarter. Finally, Parkside Financial Bank & Trust boosted its stake in Amgen by 0.4% in the second quarter. Parkside Financial Bank & Trust now owns 1,463 shares of the medical research company’s stock worth $223,000 after buying an additional 6 shares in the last quarter. 79.18% of the stock is owned by hedge funds and other institutional investors.
Shares of Amgen Inc. (NASDAQ:AMGN) traded down 0.39% during trading on Monday, reaching $172.29. The company’s stock had a trading volume of 1,313,324 shares. The firm has a market cap of $128.93 billion, a PE ratio of 17.63 and a beta of 0.87. The stock’s 50 day moving average price is $171.85 and its 200-day moving average price is $158.72. Amgen Inc. has a 12 month low of $130.09 and a 12 month high of $176.64.
Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Wednesday, July 27th. The medical research company reported $2.84 EPS for the quarter, topping analysts’ consensus estimates of $2.74 by $0.10. Amgen had a net margin of 33.07% and a return on equity of 29.30%. The business earned $5.69 billion during the quarter, compared to analysts’ expectations of $5.58 billion. During the same period last year, the company posted $2.57 EPS. The business’s revenue was up 5.9% on a year-over-year basis. Equities analysts predict that Amgen Inc. will post $11.36 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which was paid on Thursday, September 8th. Shareholders of record on Wednesday, August 17th were paid a $1.00 dividend. The ex-dividend date of this dividend was Monday, August 15th. This represents a $4.00 dividend on an annualized basis and a dividend yield of 2.31%. Amgen’s payout ratio is currently 40.90%.
A number of equities research analysts recently weighed in on the company. Leerink Swann reaffirmed a “hold” rating on shares of Amgen in a report on Saturday. Credit Suisse Group AG set a $206.00 target price on Amgen and gave the company a “buy” rating in a research note on Saturday. Vetr raised Amgen from a “hold” rating to a “buy” rating and set a $159.50 target price for the company in a research note on Monday, June 13th. Jefferies Group reissued a “buy” rating and issued a $187.00 target price on shares of Amgen in a research note on Wednesday, July 13th. Finally, Robert W. Baird reissued a “neutral” rating and issued a $157.00 target price on shares of Amgen in a research note on Friday, July 15th. One research analyst has rated the stock with a sell rating, nine have given a hold rating and thirteen have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $184.87.
In other Amgen news, VP Annette Louise Such sold 3,000 shares of Amgen stock in a transaction on Tuesday, August 2nd. The shares were sold at an average price of $174.59, for a total value of $523,770.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.20% of the stock is currently owned by company insiders.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.